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Identity 
Other names: DKFZp686B01212, DKFZp686P11128, 
SM22, SMCC, TAGLN1, WS3-10 




5.4 kb gene located on 11q23.2 consisting of 5 exons, a 
large intron 1 and 3 short introns. Several putative 
promoters present in 800 bp upstream region. 
Transcription 
A 1566 bp transcript is generated from TAGLN. All 
exon 1 and first 12 bp of exon 2 are untranslated. As 
are the last 432 bp of exon 5. 
Protein 
Note 









A 201 aa peptide member of the calponin family of 
actin binding proteins by virtue of a N-terminal 
calponin homologue domain and a single C-terminal 
calponin-like module. This C-terminal CLIK is 
required for actin binding. 
 
Figure 1. Gene structure showing 5 exonic regions (boxes) and 4 intronic regions (lines). Expanded promoter provides relative positions 
of promoters upstream (-) and downstream (+) of start site. CarG = serum response binding box; TCE = TGF-beta control element; SBE 
= Smad binding element. Resulting transcript is given, with 5' and 3' UTRs (broken line) and translated region (solid line). 
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Figure 2. Primary protein structure with amino acid (aa) positions of the calponin homologue (CH) region with calcium binding site (EF-
hand) and actin binding calponin-like (CLIK) region. CKII and PKC refer to putative caseine kinase II and protein kinase C 
phosphorylation sites respectively. 
 
Expression 
Expression profiles are a point of debate. It is found 
throughout normal smooth muscle of adult vertebrates. 
It is also found outside of smooth muscle in the spinal 
chord, adrenal gland and heart, mesenchymal cells and 
fibroblasts, epithelium of the intestine, glomerular, 
breast and prostate. 
Localisation 
It is localised to the cytosol where it binds to F-actin. 
Function 
Transgelin is an actin stress fibre binding protein. It 
gels and stabilises actin gels. In the embryo it is 
involved in podosome formation and myocyte 
migration, vascular and visceral smooth muscle cell 
differentiation, and in the suppression of matrix metallo 
protease 9 (MMP9) where it is thought to be involved 
in the suppression of tissue re-modelling following 
muscle cell differentiation. Similarly in the adult, it is 
thought to suppress tumour cell invasion through 
MMP-9 suppression. Furthermore, it has been reported 
to suppress translocation of androgen receptor to the 
nucleus. Its expression is down-regulated in many cell 
lines, and this may be an early marker of the onset of 
transformation. Indeed it is becoming increasingly 




Disorganisation of the actin cytoskeleton is a 
fundamental event of the developing cancer cell 
phenotype. Transgelin is one of several proteins that 
bind actin and subsequently cross-link and bundle 
filaments into stress fibres. Expression is decreased in 
prostate, breast and colon cancers. 
Prostate cancer 
Note 
Transgelin is one of the 2% most significant of all 
down regulated genes in prostate cancer. Its expression 
has been shown to decrease with disease progression 
with lowest expression in metastasised lesions. Loss of 
transgelin may be significant to suppression of 
androgen induced proliferation of androgen dependant 
prostate cancer as it prevents  
binding of a co-activator to androgen receptor, thereby 
blocking nuclear translocation and resulting in 
suppression of androgen mediated cell growth. Recent 
studies suggest that transgelin promotes p53 mediated 
mitochondrial dependent apotptosis. Indeed 
coimmunoprecipitation and two hybrid studies have 
shown p53 and transgelin to be binding partners, with 
re-expression of transgelin promoting cytoplasmic p53 
translocation in the prostate cancer cell line LNCaP. 
The value of transgelin as a target for selenium 
treatment has very recently been highlighted in a mouse 
model of prostate cancer (TRAMP mouse) where 






Loss of transgelin is closely associated with 
progression, differentiation and metastasis of colon 
cancer. Restoration of transgelin expression both in 
vitro and in vivo inhibits carcinogenesis. Decreased 
expression of transgelin in patients with colorectal 
cancer is associated with elevated levels of anti-
transgelin antibodies, particularly during later stages, 
and subsequently with lower survival. 
Prognosis 
Decreased transgelin is associated with poor prognosis. 
Breast cancer 
Note 
Expression of transgelin occurs early in the disease 
process, possibly through constitutive ras activation. 
Prognosis 
Unknown. 
Ischaemic heart disease and vascular 
inflammation 
Note 
Coronary arteries of the ischemic heart display 
increased abundance of transgelin. In TAGLN null 
mice inflammatory response is increased following 
carotid artery injury. It is suggested that transgelin 
suppresses pro-inflamatory NF kappa B and oxidative 
stress (via suppression of superoxide dismutase and 
p47 phox). 
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